We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia.
- Authors
Othman, Tamer; Koller, Paul; Pourhassan, Hoda; Agrawal, Vaibhav; Ngo, Dat; Tinajero, Jose; Ali, Haris; Cai, Ji‐Lian; Mei, Matthew; Aribi, Ahmed; Stein, Anthony S.; Marcucci, Guido; Forman, Stephen J.; Pullarkat, Vinod; Aldoss, Ibrahim
- Abstract
This article examines the use of tyrosine kinase inhibitor (TKI) therapy as a maintenance treatment after chimeric antigen receptor (CAR) T-cell therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who cannot undergo allogeneic hematopoietic cell transplantation (alloHCT). The study presents a case series of seven patients who received CAR-T cells for relapsed/refractory Ph+ ALL and subsequently received TKI maintenance. The article discusses the patients' characteristics and outcomes, emphasizing the need for further research and data on this approach. The study suggests that TKI maintenance therapy after CAR-T may be beneficial, particularly in patients who achieve complete molecular remission (CMR) and have no evidence of minimal residual disease (MRD). The authors recommend larger prospective trials to confirm the effectiveness and safety of TKI maintenance therapy post-CAR-T, and to explore its potential application to other subtypes of ALL.
- Subjects
INFORMED consent (Medical law); REGULATORY T cells; CYTOKINE release syndrome; CHILD patients; T-cell exhaustion
- Publication
British Journal of Haematology, 2024, Vol 205, Issue 2, p711
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.19551